Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin, RAFTILOSE Synergy 1, and Sulindac in Preventing Colorectal Neoplasia
NCT00335504Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2006
- Primary completion
- Apr 2009
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atorvastatin, sulindac, oligofructose-enriched inulin in Colorectal neoplasia, sponsored by National Cancer Institute. Started Mar 2006; status: completed.
02
Drugs
atorvastatinsulindacoligofructose-enriched inulin
03
Conditions
Colorectal neoplasia
Beyond the preview
Go deeper on NCT00335504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00335504.